

# Geoffrey R Hill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8614477/publications.pdf>

Version: 2024-02-01

238  
papers

16,461  
citations

9254

74  
h-index

19169

118  
g-index

242  
all docs

242  
docs citations

242  
times ranked

17963  
citing authors

#	ARTICLE	IF	CITATIONS
1	Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines. <i>Blood</i> , 1997, 90, 3204-3213.	0.6	765
2	The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. <i>Blood</i> , 2000, 95, 2754-2759.	0.6	643
3	An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. <i>Blood</i> , 2010, 116, 3955-3963.	0.6	410
4	MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. <i>Journal of Clinical Investigation</i> , 2007, 117, 2313-2324.	3.9	351
5	Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.. <i>Journal of Clinical Investigation</i> , 1998, 102, 1882-1891.	3.9	306
6	LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. <i>Journal of Clinical Investigation</i> , 2001, 107, 1581-1589.	3.9	258
7	Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.. <i>Journal of Clinical Investigation</i> , 1998, 102, 115-123.	3.9	256
8	Differential roles of IL-1 and TNF- $\alpha$ on graft-versus-host disease and graft versus leukemia. <i>Journal of Clinical Investigation</i> , 1999, 104, 459-467.	3.9	229
9	Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. <i>Blood</i> , 2017, 129, 13-21.	0.6	216
10	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
11	Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. <i>Nature Medicine</i> , 2012, 18, 135-142.	15.2	206
12	TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. <i>Blood</i> , 2018, 132, 1689-1694.	0.6	198
13	CYTOKINE CASCADES IN ACUTE GRAFT-VERSUS-HOST DISEASE1. <i>Transplantation</i> , 1997, 64, 553-558.	0.5	195
14	Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1451-1459.	5.1	194
15	Innate immunity defines the capacity of antiviral T cells to limit persistent infection. <i>Journal of Experimental Medicine</i> , 2010, 207, 1333-1343.	4.2	190
16	The Colony-Stimulating Factor 1 Receptor Is Expressed on Dendritic Cells during Differentiation and Regulates Their Expansion. <i>Journal of Immunology</i> , 2005, 175, 1399-1405.	0.4	179
17	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	0.6	179
18	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	3.9	173

#	ARTICLE	IF	CITATIONS
19	CSF-1 <sup>+</sup> dependant donor-derived macrophages mediate chronic graft-versus-host disease. Journal of Clinical Investigation, 2014, 124, 4266-4280.	3.9	173
20	Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease. Blood, 1999, 94, 825-831.	0.6	168
21	Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	5.8	166
22	MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. Immunity, 2019, 51, 885-898.e7.	6.6	164
23	Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. Cancer Cell, 2018, 33, 634-648.e5.	7.7	163
24	IFN <sup>γ</sup> differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood, 2007, 110, 1064-1072.	0.6	159
25	CD4 <sup>+</sup> CD25 <sup>+</sup> regulatory T cells control CD8 <sup>+</sup> T-cell effector differentiation by modulating IL-2 homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7529-7534.	3.3	159
26	IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. Journal of Clinical Investigation, 1999, 104, 317-325.	3.9	159
27	Heat Shock Protein 10 Inhibits Lipopolysaccharide-induced Inflammatory Mediator Production. Journal of Biological Chemistry, 2005, 280, 4037-4047.	1.6	158
28	TRAIL <sup>+</sup> NK Cells Control CD4 <sup>+</sup> T Cell Responses during Chronic Viral Infection to Limit Autoimmunity. Immunity, 2014, 41, 646-656.	6.6	158
29	Cytokines in Graft-versus-Host Disease. Journal of Immunology, 2015, 194, 4604-4612.	0.4	156
30	A Role for Natural Regulatory T Cells in the Pathogenesis of Experimental Cerebral Malaria. American Journal of Pathology, 2007, 171, 548-559.	1.9	155
31	Immune-Mediated Mechanisms of Parasite Tissue Sequestration during Experimental Cerebral Malaria. Journal of Immunology, 2010, 185, 3632-3642.	0.4	155
32	Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation. Clinical Cancer Research, 2011, 17, 77-88.	3.2	155
33	The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood, 2014, 124, 354-362.	0.6	153
34	PD-1 Dependent Exhaustion of CD8 <sup>+</sup> T Cells Drives Chronic Malaria. Cell Reports, 2013, 5, 1204-1213.	2.9	147
35	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood, 2016, 127, 2144-2154.	0.6	145
36	Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- $\gamma$ in a murine model of polycythemia vera. Blood, 2013, 121, 3692-3702.	0.6	140

#	ARTICLE	IF	CITATIONS
37	Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. <i>Blood</i> , 2010, 116, 819-828.	0.6	139
38	TGF- $\beta$ 2 in allogeneic stem cell transplantation: friend or foe?. <i>Blood</i> , 2005, 106, 2206-2214.	0.6	136
39	Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. <i>Blood</i> , 2004, 103, 3573-3581.	0.6	133
40	The p55 TNF- $\alpha$ Receptor Plays a Critical Role in T Cell Alloreactivity. <i>Journal of Immunology</i> , 2000, 164, 656-663.	0.4	130
41	Cytokine Expanded Myeloid Precursors Function as Regulatory Antigen-Presenting Cells and Promote Tolerance through IL-10-Producing Regulatory T Cells. <i>Journal of Immunology</i> , 2005, 174, 1841-1850.	0.4	128
42	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- $\beta$ 2 production. <i>Blood</i> , 2017, 129, 2570-2580.	0.6	122
43	Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. <i>Blood</i> , 2006, 108, 2485-2492.	0.6	121
44	TUMOR NECROSIS FACTOR- $\alpha$ NEUTRALIZATION REDUCES LUNG INJURY AFTER EXPERIMENTAL ALLOGENEIC BONE MARROW TRANSPLANTATION1. <i>Transplantation</i> , 2000, 70, 272-279.	0.5	120
45	Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. <i>Blood</i> , 2018, 132, 1675-1688.	0.6	119
46	Eomesodermin promotes the development of type 1 regulatory T (T <sub>R</sub> 1) cells. <i>Science Immunology</i> , 2017, 2, .	5.6	118
47	CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells. <i>Nature Communications</i> , 2015, 6, 8644.	5.8	117
48	IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8328-8333.	3.3	116
49	Identification and expansion of highly suppressive CD8 <sup>+</sup> FoxP3 <sup>+</sup> regulatory T cells after experimental allogeneic bone marrow transplantation. <i>Blood</i> , 2012, 119, 5898-5908.	0.6	114
50	NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. <i>Journal of Clinical Investigation</i> , 2005, 115, 3093-3103.	3.9	114
51	Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. <i>Blood</i> , 2018, 131, 2651-2660.	0.6	113
52	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. <i>Journal of Clinical Investigation</i> , 2015, 125, 2077-2089.	3.9	111
53	The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. <i>Nature Immunology</i> , 2020, 21, 1205-1218.	7.0	110
54	Granulocyte Colony-Stimulating Factor- $\alpha$ Mobilized Allogeneic Stem Cell Transplantation Maintains Graft-Versus-Leukemia Effects Through a Perforin-Dependent Pathway While Preventing Graft-Versus-Host Disease. <i>Blood</i> , 1999, 93, 4071-4078.	0.6	108

#	ARTICLE	IF	CITATIONS
55	Immunotherapy of multiple myeloma. <i>Journal of Clinical Investigation</i> , 2020, 130, 1565-1575.	3.9	103
56	Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?. <i>Blood</i> , 2006, 107, 3430-3435.	0.6	102
57	Induced Regulatory T Cells Promote Tolerance When Stabilized by Rapamycin and IL-2 In Vivo. <i>Journal of Immunology</i> , 2013, 191, 5291-5303.	0.4	101
58	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	0.6	101
59	Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1569-1589.	2.4	100
60	Mouse Models of Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 129-135.	2.0	98
61	CD4+ Natural Regulatory T Cells Prevent Experimental Cerebral Malaria via CTLA-4 When Expanded In Vivo. <i>PLoS Pathogens</i> , 2010, 6, e1001221.	2.1	98
62	Type I interferons suppress CD4 <sup>+</sup> T cell-dependent parasite control during blood-stage <i>Plasmodium</i> infection. <i>European Journal of Immunology</i> , 2011, 41, 2688-2698.	1.6	98
63	Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects. <i>Blood</i> , 2015, 126, 1609-1620.	0.6	98
64	Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis. <i>Cancer Immunology Research</i> , 2017, 5, 1098-1108.	1.6	98
65	Type I IFN signaling in CD8 <sup>+</sup> DCs impairs Th1-dependent malaria immunity. <i>Journal of Clinical Investigation</i> , 2014, 124, 2483-2496.	3.9	96
66	CD8 <sup>+</sup> DCs can be induced in the absence of transcription factors Id2, Nfil3, and Batf3. <i>Blood</i> , 2013, 121, 1574-1583.	0.6	95
67	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. <i>Blood</i> , 2016, 128, 1013-1017.	0.6	95
68	Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. <i>Blood</i> , 2018, 131, 1858-1869.	0.6	94
69	Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. <i>PLoS Pathogens</i> , 2016, 12, e1005398.	2.1	92
70	Essential Role for the P55 Tumor Necrosis Factor Receptor in Regulating Hematopoiesis at a Stem Cell Level. <i>Journal of Experimental Medicine</i> , 1999, 190, 1493-1504.	4.2	85
71	Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. <i>Journal of Experimental Medicine</i> , 2015, 212, 1303-1321.	4.2	85
72	NK cells require IL-28R for optimal in vivo activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2376-84.	3.3	82

#	ARTICLE	IF	CITATIONS
73	G-CSF MODULATES CYTOKINE PROFILE OF DENDRITIC CELLS AND DECREASES ACUTE GRAFT-VERSUS-HOST DISEASE THROUGH EFFECTS ON THE DONOR RATHER THAN THE RECIPIENT. <i>Transplantation</i> , 2000, 69, 691-693.	0.5	82
74	Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2016, 7, 144.	2.2	81
75	Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 475-492.	12.5	80
76	Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. <i>Blood</i> , 2009, 113, 5644-5649.	0.6	79
77	Current Concepts and Advances in Graft-Versus-Host Disease Immunology. <i>Annual Review of Immunology</i> , 2021, 39, 19-49.	9.5	79
78	Clinical Assessment of Anti-Viral CD8+ T Cell Immune Monitoring Using QuantiFERON-CMV <sup>®</sup> Assay to Identify High Risk Allogeneic Hematopoietic Stem Cell Transplant Patients with CMV Infection Complications. <i>PLoS ONE</i> , 2013, 8, e74744.	1.1	78
79	Recipient mucosal-associated invariant T cells control GVHD within the colon. <i>Journal of Clinical Investigation</i> , 2018, 128, 1919-1936.	3.9	78
80	The IL-17 Differentiation Pathway and Its Role in Transplant Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S56-S61.	2.0	74
81	Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy. <i>Cell Stem Cell</i> , 2014, 15, 775-790.	5.2	74
82	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. <i>Cancer Research</i> , 2016, 76, 6266-6277.	0.4	74
83	Cytokine mediators of chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 2452-2463.	3.9	74
84	Hyporesponsiveness of Donor Cells to Lipopolysaccharide Stimulation Reduces the Severity of Experimental Idiopathic Pneumonia Syndrome: Potential Role for a Gut-Lung Axis of Inflammation. <i>Journal of Immunology</i> , 2000, 165, 6612-6619.	0.4	73
85	Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation. <i>Blood</i> , 2015, 125, 2435-2444.	0.6	73
86	Allergen-induced IL-6 trans-signaling activates $\gamma\delta$ T cells to promote type 2 and type 17 airway inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1065-1073.	1.5	73
87	Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. <i>Bone Marrow Transplantation</i> , 2000, 26, 309-313.	1.3	68
88	CD3 <sup>bright</sup> signals on $\gamma\delta$ T cells identify IL-17A-producing $\gamma\delta$ T cells. <i>Immunology and Cell Biology</i> , 2015, 93, 198-212.	1.0	68
89	Disseminated Varicella Infection Caused by Varicella Vaccine Strain in a Child With Low Invariant Natural Killer T Cells and Diminished CD1d Expression. <i>Journal of Infectious Diseases</i> , 2011, 204, 1893-1901.	1.9	67
90	Cytokines and costimulation in acute graft-versus-host disease. <i>Blood</i> , 2020, 136, 418-428.	0.6	66

#	ARTICLE	IF	CITATIONS
91	Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. <i>Blood</i> , 2003, 101, 2033-2042.	0.6	64
92	Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. <i>Nature Medicine</i> , 2009, 15, 436-441.	15.2	64
93	Type I-IFNs control GVHD and GVL responses after transplantation. <i>Blood</i> , 2011, 118, 3399-3409.	0.6	64
94	Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome. <i>Blood</i> , 2017, 129, 2172-2185.	0.6	63
95	Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD. <i>Blood</i> , 2007, 109, 5049-5057.	0.6	60
96	Reduced Mucosal Associated Invariant T-Cells Are Associated with Increased Disease Severity and <i>Pseudomonas aeruginosa</i> Infection in Cystic Fibrosis. <i>PLoS ONE</i> , 2014, 9, e109891.	1.1	58
97	Combination antithymocyte globulin and soluble TNF inhibitor (etanercept) + mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2006, 37, 1143-1147.	1.3	57
98	Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. <i>Blood</i> , 2018, 132, 2707-2721.	0.6	56
99	Granulocyte-colony stimulating factor increases CD123 <sup>hi</sup> blood dendritic cells with altered CD62L and CCR7 expression. <i>Blood</i> , 2003, 101, 2314-2317.	0.6	55
100	The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease. <i>Blood</i> , 2019, 134, 2139-2148.	0.6	55
101	Activation of Invariant NKT Cells Exacerbates Experimental Visceral Leishmaniasis. <i>PLoS Pathogens</i> , 2008, 4, e1000028.	2.1	53
102	The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia. <i>Blood</i> , 2018, 131, 1148-1153.	0.6	53
103	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017, 2, .	2.3	53
104	IFNAR1-Signalling Obstructs ICOS-mediated Humoral Immunity during Non-lethal Blood-Stage <i>Plasmodium</i> Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005999.	2.1	52
105	Alloantigen presentation and graft-versus-host disease: fuel for the fire. <i>Blood</i> , 2016, 127, 2963-2970.	0.6	50
106	Soluble lymphotoxin is an important effector molecule in GVHD and GVL. <i>Blood</i> , 2010, 115, 122-132.	0.6	49
107	Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. <i>Blood</i> , 2016, 128, 794-804.	0.6	49
108	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. <i>Blood</i> , 2019, 134, 1670-1682.	0.6	49

#	ARTICLE	IF	CITATIONS
109	Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation. <i>Science</i> , 2019, 363, 288-293.	6.0	49
110	Bone marrow transplantation generates T cell-dependent control of myeloma in mice. <i>Journal of Clinical Investigation</i> , 2018, 129, 106-121.	3.9	49
111	Graft-versus-Host Disease Prevents the Maturation of Plasmacytoid Dendritic Cells. <i>Journal of Immunology</i> , 2009, 182, 912-920.	0.4	47
112	Promoting regulation via the inhibition of DNAM-1 after transplantation. <i>Blood</i> , 2013, 121, 3511-3520.	0.6	47
113	A critical role for donor-derived IL-22 in cutaneous chronic GVHD. <i>American Journal of Transplantation</i> , 2018, 18, 810-820.	2.6	45
114	Advances in the understanding of acute graft-versus-host disease. <i>British Journal of Haematology</i> , 2007, 137, 3-19.	1.2	44
115	Common Strategies To Prevent and Modulate Experimental Cerebral Malaria in Mouse Strains with Different Susceptibilities. <i>Infection and Immunity</i> , 2008, 76, 3312-3320.	1.0	43
116	Î±-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice. <i>Blood</i> , 2015, 125, 3014-3023.	0.6	43
117	Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. <i>JCI Insight</i> , 2016, 1, e86850.	2.3	43
118	IL-6 promotes CD4 <sup>+</sup> T cell and B cell activation during <i>Plasmodium</i> infection. <i>Parasite Immunology</i> , 2017, 39, e12455.	0.7	42
119	Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated G-CSF. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 603-607.	2.0	40
120	The interferon-dependent orchestration of innate and adaptive immunity after transplantation. <i>Blood</i> , 2012, 119, 5351-5358.	0.6	40
121	VCAM-1 and VLA-4 Modulate Dendritic Cell IL-12p40 Production in Experimental Visceral Leishmaniasis. <i>PLoS Pathogens</i> , 2008, 4, e1000158.	2.1	39
122	SOCS3 regulates graft-versus-host disease. <i>Blood</i> , 2010, 116, 287-296.	0.6	37
123	Autophagy is required for stem cell mobilization by G-CSF. <i>Blood</i> , 2015, 125, 2933-2936.	0.6	36
124	Interferon-Î³-Dependent Migration of Microglial Cells in the Retina after Systemic Cytomegalovirus Infection. <i>American Journal of Pathology</i> , 2013, 182, 875-885.	1.9	34
125	UVB-Induced Melanocyte Proliferation in Neonatal Mice Driven by CCR2-Independent Recruitment of Ly6clowMHCIIhi Macrophages. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1803-1812.	0.3	34
126	Modification of T Cell Responses by Stem Cell Mobilization Requires Direct Signaling of the T Cell by G-CSF and IL-10. <i>Journal of Immunology</i> , 2014, 192, 3180-3189.	0.4	34



#	ARTICLE	IF	CITATIONS
127	Distinct Roles for CD4+ Foxp3+ Regulatory T Cells and IL-10-Mediated Immunoregulatory Mechanisms during Experimental Visceral Leishmaniasis Caused by <i>Leishmania donovani</i> . <i>Journal of Immunology</i> , 2018, 201, 3362-3372.	0.4	34
128	Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. <i>Cell Reports</i> , 2020, 30, 2512-2525.e9.	2.9	34
129	Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subsets. <i>Blood</i> , 2012, 119, 5918-5930.	0.6	32
130	Cross-Dressing by Donor Dendritic Cells after Allogeneic Bone Marrow Transplantation Contributes to Formation of the Immunological Synapse and Maximizes Responses to Indirectly Presented Antigen. <i>Journal of Immunology</i> , 2014, 192, 5426-5433.	0.4	32
131	GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity. <i>Blood</i> , 2017, 129, 630-642.	0.6	32
132	A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. <i>Blood</i> , 2021, 137, 1970-1979.	0.6	32
133	IFN Regulatory Factor 3 Balances Th1 and T Follicular Helper Immunity during Nonlethal Blood-Stage <i>Plasmodium</i> Infection. <i>Journal of Immunology</i> , 2018, 200, 1443-1456.	0.4	31
134	Successful Immunotherapy of HCMV Disease Using Virus-Specific T Cells Expanded from an Allogeneic Stem Cell Transplant Recipient. <i>American Journal of Transplantation</i> , 2010, 10, 173-179.	2.6	30
135	Inflammation and Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 139-141.	2.0	29
136	Immunotherapy with Costimulatory Dendritic Cells To Control Autoimmune Inflammation. <i>Journal of Immunology</i> , 2011, 187, 4018-4030.	0.4	29
137	Imaging the immunological synapse between dendritic cells and T cells. <i>Journal of Immunological Methods</i> , 2015, 423, 40-44.	0.6	29
138	IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling. <i>Blood</i> , 2019, 134, 2092-2106.	0.6	29
139	Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after $\alpha$ -galactosylceramide administration. <i>Blood</i> , 2009, 113, 5999-6010.	0.6	28
140	Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model. <i>American Journal of Pathology</i> , 2016, 186, 524-538.	1.9	28
141	Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT. <i>Blood Advances</i> , 2017, 1, 341-351.	2.5	28
142	Dendritic cell immunotherapy for cancer: Application to low-grade lymphoma and multiple myeloma. <i>Immunology and Cell Biology</i> , 1999, 77, 451-459.	1.0	27
143	Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease. <i>Blood</i> , 2018, 131, 2074-2085.	0.6	27
144	Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 373-385.	2.0	26

#	ARTICLE	IF	CITATIONS
145	Critical Roles for LIGHT and Its Receptors in Generating T Cell-Mediated Immunity during Leishmania donovani Infection. <i>PLoS Pathogens</i> , 2011, 7, e1002279.	2.1	26
146	Novel platform technology for modular mucosal vaccine that protects against streptococcus. <i>Scientific Reports</i> , 2016, 6, 39274.	1.6	26
147	IL-17A-Producing $\gamma\delta$ T Cells Suppress Early Control of Parasite Growth by Monocytes in the Liver. <i>Journal of Immunology</i> , 2015, 195, 5707-5717.	0.4	25
148	PRETRANSPLANT CHEMOTHERAPY REDUCES INFLAMMATORY CYTOKINE PRODUCTION AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1999, 67, 1478-1480.	0.5	25
149	The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells. <i>British Journal of Haematology</i> , 2017, 177, 423-440.	1.2	24
150	Granulocytes Are Unresponsive to IL-6 Due to an Absence of gp130. <i>Journal of Immunology</i> , 2018, 200, 3547-3555.	0.4	24
151	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. <i>JHEP Reports</i> , 2022, 4, 100386.	2.6	22
152	Keratinocyte Growth Factor (KGF) in Hematology and Oncology. <i>Current Pharmaceutical Design</i> , 2002, 8, 395-403.	0.9	21
153	Donor T-cell-derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract. <i>Blood Advances</i> , 2019, 3, 2859-2865.	2.5	21
154	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019, 133, 94-99.	0.6	21
155	IFN- $\gamma$ therapy prevents severe gastrointestinal graft-versus-host disease. <i>Blood</i> , 2021, 138, 722-737.	0.6	21
156	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641.	0.6	21
157	Pulmonary hypertension as a consequence of alveolar capillary plugging by malignant megakaryocytes in essential thrombocythaemia. <i>Australian and New Zealand Journal of Medicine</i> , 1996, 26, 852-853.	0.5	20
158	Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice. <i>Blood</i> , 2015, 126, 1503-1514.	0.6	20
159	Flt-3L Expansion of Recipient CD8 $^+$ Dendritic Cells Deletes Alloreactive Donor T Cells and Represents an Alternative to Posttransplant Cyclophosphamide for the Prevention of GVHD. <i>Clinical Cancer Research</i> , 2018, 24, 1604-1616.	3.2	20
160	Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. <i>JCI Insight</i> , 2019, 4, .	2.3	20
161	Impact of cytokine gene polymorphisms on graft-versus-host disease. <i>Tissue Antigens</i> , 2008, 72, 507-516.	1.0	19
162	CpG pretreatment enhances antiviral T-cell immunity against cytomegalovirus. <i>Blood</i> , 2013, 122, 55-60.	0.6	18

#	ARTICLE	IF	CITATIONS
163	Atypical chemokine receptor 4 shapes activated B cell fate. <i>Journal of Experimental Medicine</i> , 2018, 215, 801-813.	4.2	18
164	Phase I Trial of Inducible Caspase 9 T Cells in Adult Stem Cell Transplant Demonstrates Massive Clonotypic Proliferative Potential and Long-term Persistence of Transgenic T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 1749-1755.	3.2	18
165	Therapeutic Glucocorticoid-Induced TNF Receptor-Mediated Amplification of CD4+T Cell Responses Enhances Antiparasitic Immunity. <i>Journal of Immunology</i> , 2010, 184, 2583-2592.	0.4	17
166	Continuous pre- and post-transplant exposure to a disease-associated gut microbiome promotes hyper-acute graft-versus-host disease in wild-type mice. <i>Gut Microbes</i> , 2020, 11, 754-770.	4.3	17
167	CMV exposure drives long-term CD57+ CD4 memory T-cell inflation following allogeneic stem cell transplant. <i>Blood</i> , 2021, 138, 2874-2885.	0.6	16
168	Cytokine Dysregulation in Acute Graft-versus-Host Disease. <i>Hematology</i> , 1997, 2, 423-434.	0.7	15
169	Tolerance induction with gene-modified stem cells and immune-preserving conditioning in primed mice: restricting antigen to differentiated antigen-presenting cells permits efficacy. <i>Blood</i> , 2013, 121, 1049-1058.	0.6	15
170	IL-27 signalling regulates glycolysis in Th1 cells to limit immunopathology during infection. <i>PLoS Pathogens</i> , 2020, 16, e1008994.	2.1	15
171	Immune control of cytomegalovirus reactivation in stem cell transplantation. <i>Blood</i> , 2022, 139, 1277-1288.	0.6	15
172	The Pathophysiology and Treatment of Graft-Versus-Host Disease: Lessons Learnt From Animal Models. <i>Frontiers in Immunology</i> , 2021, 12, 715424.	2.2	15
173	Recipient plasmacytoid DCs are not required to prime allogeneic T-cell responses after BMT. <i>Blood</i> , 2009, 113, 6038-6039.	0.6	14
174	Pegylated interferon-2 $\pm$ invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 3013-3019.	2.5	14
175	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020, 135, 28-40.	0.6	14
176	Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. <i>Bone Marrow Transplantation</i> , 2014, 49, 110-115.	1.3	12
177	Development of a Multiplexed Microsphere PCR for Culture-Free Detection and Gram-Typing of Bacteria in Human Blood Samples. <i>ACS Infectious Diseases</i> , 2018, 4, 837-844.	1.8	12
178	Single-cell transcriptomics of alloreactive CD4+ T cells over time reveals divergent fates during gut graft-versus-host disease. <i>JCI Insight</i> , 2020, 5, .	2.3	12
179	Allergen-encoding bone marrow transfer inactivates allergic T cell responses, alleviating airway inflammation. <i>JCI Insight</i> , 2017, 2, .	2.3	12
180	Relapsed Plasma Cell Leukaemia Presenting with Aggressive Extramedullary Plasmacytomas in the Meninges and Testis--A Missed Opportunity for Induction CNS Prophylaxis. <i>Leukemia and Lymphoma</i> , 2002, 43, 893-896.	0.6	10

#	ARTICLE	IF	CITATIONS
181	Activation of the zinc-sensing receptor GPR39 promotes T-cell reconstitution after hematopoietic cell transplant in mice. <i>Blood</i> , 2022, 139, 3655-3666.	0.6	10
182	A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. <i>Bone Marrow Transplantation</i> , 2005, 36, 553-554.	1.3	9
183	Early Blood Stream Infections after BMT are Associated with Cytokine Dysregulation and Poor Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1360-1366.	2.0	9
184	Effect of plasmapheresis on ATG (Thymoglobulin) clearance prior to adoptive T cell transfer. <i>Bone Marrow Transplantation</i> , 2019, 54, 2110-2116.	1.3	9
185	Targeting PI3K $\hat{\nu}$ function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	2.6	9
186	Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience. <i>International Journal of Laboratory Hematology</i> , 2006, 28, 189-197.	0.2	8
187	Autophagy and haematopoietic stem cell transplantation. <i>Immunology and Cell Biology</i> , 2015, 93, 43-50.	1.0	8
188	Acute myeloid leukemia stem cell function is preserved in the absence of autophagy. <i>Haematologica</i> , 2017, 102, e344-e347.	1.7	8
189	Epigenetic programming of T cells impacts immune reconstitution in hematopoietic stem cell transplant recipients. <i>Blood Advances</i> , 2018, 2, 656-668.	2.5	8
190	Interleukin-10 mediated immune regulation after stem cell transplantation: Mechanisms and implications for therapeutic intervention. <i>Seminars in Immunology</i> , 2019, 44, 101322.	2.7	8
191	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. <i>Blood</i> , 2021, 137, 1090-1103.	0.6	8
192	Autologous Stem Cell Transplantation for Myeloma: Cyto-reduction or an Immunotherapy?. <i>Frontiers in Immunology</i> , 2021, 12, 651288.	2.2	8
193	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. <i>JCI Insight</i> , 2019, 4, .	2.3	8
194	Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease. <i>Blood</i> , 1999, 94, 825-831.	0.6	8
195	Donor Treatment with a Multi-pegylated G-CSF Maximizes Graft-versus-Leukemia Effects. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 126-130.	2.0	7
196	The early monocytic response to cytomegalovirus infection is MyD88 dependent but occurs independently of common inflammatory cytokine signals. <i>European Journal of Immunology</i> , 2014, 44, 409-419.	1.6	7
197	Origin of Langerhans cells in normal skin and chronic GVHD after hematopoietic stem-cell transplantation. <i>Experimental Dermatology</i> , 2014, 23, 75-77.	1.4	7
198	Expansion of IL-17A $\hat{\nu}$ secreting CD8 $\hat{\nu}$ mucosa-associated invariant T cells in peripheral blood following stem cell mobilization. <i>Blood Advances</i> , 2019, 3, 718-723.	2.5	7

#	ARTICLE	IF	CITATIONS
199	Adult-related haematopoietic stem cell donor experiences and the provision of information and psychosocial support: A systematic literature review. <i>European Journal of Cancer Care</i> , 2019, 28, e12932.	0.7	7
200	Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT. <i>JCI Insight</i> , 2021, 6, .	2.3	7
201	IFN- $\gamma$ Diminishes the Severity of Viral Bronchiolitis in Neonatal Mice by Limiting NADPH Oxidase-Induced PAD4-Independent NETosis. <i>Journal of Immunology</i> , 2022, 208, 2806-2816.	0.4	7
202	Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution. <i>Journal of Virology</i> , 2016, 90, 7497-7507.	1.5	6
203	Mouse Models of Antigen Presentation in Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 715893.	2.2	6
204	ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome. <i>Cancer Immunology Research</i> , 2020, 8, 1085-1098.	1.6	6
205	BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. <i>Blood</i> , 2022, 139, 2983-2997.	0.6	6
206	The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations. <i>International Journal of Laboratory Hematology</i> , 1997, 19, 155-157.	0.2	5
207	Post transplant CMV-specific T-cell immune reconstitution in the absence of global T-cell immunity is associated with a high risk of subsequent virus reactivation. <i>Bone Marrow Transplantation</i> , 2015, 50, 315-316.	1.3	5
208	Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling. <i>Haematologica</i> , 2016, 101, e77-e80.	1.7	5
209	Donor leukocyte infusions in the treatment of chronic myeloid leukemia in relapse post bone marrow transplantation. <i>Pathology</i> , 1996, 28, 51-53.	0.3	4
210	Immunotherapy following relapse of acute leukaemia after T-cell-replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft-versus-host disease. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 197-204.	0.7	4
211	Conventional dendritic cells are required for the cross-presentation of leukemia-specific antigen in a model of AML relapse post-BMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 800-803.	1.3	4
212	Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience. <i>Blood Cancer Journal</i> , 2017, 7, 655.	2.8	3
213	Experiences and unmet needs of family members requested to donate haematopoietic stem cells to an ill relative: findings from a prospective multi-centre study. <i>Supportive Care in Cancer</i> , 2021, 29, 635-644.	1.0	3
214	TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Ibrandomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2745-2745.	0.6	3
215	Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 429-439.	2.5	3
216	Host $\gamma$ T cells: an innate bridge to the epithelial targets of GVHD?. <i>Blood</i> , 2005, 106, 393-394.	0.6	2

#	ARTICLE	IF	CITATIONS
217	Twenty-four hour continuous infusion of amphotericin B for the treatment of suspected or proven fungal infection in haematology patients. <i>Internal Medicine Journal</i> , 2005, 35, 374-374.	0.5	2
218	Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation. <i>Leukemia</i> , 2005, 19, 317-318.	3.3	2
219	Vaccinating donors to improve GVL. <i>Blood</i> , 2011, 118, 5720-5721.	0.6	2
220	Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD. <i>Bone Marrow Transplantation</i> , 2016, 51, 1153-1155.	1.3	2
221	Cytokines in GVHD and GVL. , 2019, , 293-322.		2
222	Adult related haematopoietic stem cell donor care: Views of Transplant Nurses. <i>European Journal of Oncology Nursing</i> , 2019, 41, 56-63.	0.9	2
223	Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies. <i>Blood</i> , 2014, 124, 535-535.	0.6	2
224	Integrated Molecular Analysis Identifies Replicative Stress As Sensitizer to Imetelstat Therapy in AML. <i>Blood</i> , 2017, 130, 798-798.	0.6	2
225	Conditioning regimens for autologous haematopoietic stem cell transplantation - can natural killer cell therapy help?. <i>British Journal of Haematology</i> , 2017, 177, 341-342.	1.2	1
226	Cytokines in Hematopoietic Stem Cell Transplantation. , 2017, , 219-236.		1
227	Autophagy Is Required For Long-Term Hematopoietic Stem Cell (HSC) Function and G-CSF-Induced HSC Mobilization. <i>Blood</i> , 2013, 122, 892-892.	0.6	1
228	The Combination of Anti-Tigit and Lenalidomide Promotes Synergistic Myeloma-Specific Immunity after ASCT. <i>Blood</i> , 2021, 138, 328-328.	0.6	1
229	Multiplex Microsphere PCR (mmPCR) Allows Simultaneous Gram Typing, Detection of Fungal DNA, and Antibiotic Resistance Genes. <i>Laboratory Medicine</i> , 2022, 53, 459-464.	0.8	1
230	Cytokines in graft-versus-host disease and graft-versus-leukemia. , 2013, , 357-391.		0
231	Bone Marrow Transplantation Under Regulatory T Cell Cover to Induce Donor-Specific Tolerance. <i>Transplantation</i> , 2017, 101, 232-233.	0.5	0
232	Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model. <i>Blood</i> , 2013, 122, 292-292.	0.6	0
233	Hematopoietic Stem Cells and Their Progenitors Critically Require Autophagy to Promote Early Engraftment Following Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 34-34.	0.6	0
234	Pirfenidone Reverses Murine Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 1158-1158.	0.6	0

#	ARTICLE	IF	CITATIONS
235	A Critical Role for Donor-Derived IL-22 in Cutaneous Chronic Gvhd. Blood, 2017, 130, 69-69.	0.6	0
236	Oncogenic-Drivers Dictate Immune Responses to Control Disease Progression in Acute Myeloid Leukaemia. Blood, 2018, 132, 904-904.	0.6	0
237	The IL-2/IL-15 Mimetic NL-201 Prevents Myeloma Relapse after ASCT By Expanding Highly Cytolytic T Cells in the Bone Marrow That Are Resistant to Exhaustion. Blood, 2021, 138, 1609-1609.	0.6	0
238	Recent insights to the mechanisms of graft-versus-host disease. Rinsho Ketsueki/the Japanese Journal of Clinical Hematology, 2016, 57, 2169-2175.	0.5	0